Fortress Biotech Q2 EPS $(0.17) Down From $(0.05) YoY, Sales $17.84M Up From $9.46M YoY
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.17) per share. This is a 240 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $17.84 million in sales
Dr. Reddy’s Lab, Fortress Biotech Ink DFD-29 Collaboration Pact For Chronic Skin Disorder
Journey Medical Corporation, a partner company of Fortress Biotech Inc (NASDAQ:FBIO), has entered into a collaborative development and commercialization agreement with Dr. Reddy’s…
60 Biggest Movers From Yesterday
Gainers
RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV.
Mustang Bio’s CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
Mustang Bio Inc (NASDAQ:MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas…